CompletedNot Applicable

Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: THE ENDOHEM REGISTRY

Spain1,602 participantsStarted 2018-01-01

Plain-language summary

This observational study evaluates the safety of gastrointestinal endoscopy in patients on oral anticoagulants (Vitamin K antagonists, rivaroxaban, dabigatran, edoxaban, and apixaban). This registry aims to assess the incidence, characteristics and risk factors for cardiovascular and bleeding events associated with an endoscopic procedure. Besides, it aims to evaluate the differences between Vitamin K antagonists and DOACs users and to estimate the impact of anticoagulation withdrawal time on the primary and secondary outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>= 18 years. * Patients with preoperative use of oral anticoagulants (Vitamin K antagonist, apixaban, edoxaban, rivaroxaban or dabigatrán) undergoing gastrointestinal endoscopy. * Patients on oral anticoagulants (Vitamin K antagonist, apixaban, edoxaban, rivaroxaban or dabigatran) presenting with gastrointestinal bleeding, regardless of receiving gastrointestinal endoscopy. * Signed informed consent. Exclusion Criteria: * Negative to participate in the study.

What they're measuring

Incidence of Cardiovascular events

Timeframe: 3 months

Trial details

NCT IDNCT03669068

SponsorHospital Universitario Ramon y Cajal

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-04-01

View on ClinicalTrials.gov More Gastrointestinal Bleeding trials